Abstract:Background and aim: The prevalence and severity of alcoholic liver disease (ALD) are increasing. The incidence of alcohol-related cirrhosis has risen up to 2.5%. This study aimed to identify novel metabolite mechanisms involved in the development of ALD in patients. The use of gut microbiome-derived metabolites is increasing in targeted therapies. Identifying metabolic compounds is challenging due to the complex patterns that have long-term effects on ALD. We investigated the specific metabolite signatures in ALD patients. Methods: This study included 247 patients (heathy control, HC: n = 62, alcoholic fatty liver, AFL; n = 25, alcoholic hepatitis, AH; n = 80, and alcoholic cirrhosis, AC, n = 80) identified, and stool samples were collected. 16S rRNA sequencing and metabolomics were performed with MiSeq sequencer and liquid chromatography coupled to time-of-flight-mass spectrometry (LC-TOF-MS), respectively. The untargeted metabolites in AFL, AH, and AC samples were evaluated by multivariate statistical analysis and metabolic pathotypic expression. Metabolic network classifiers were used to predict the pathway expression of the AFL, AH, and AC stages. Results: The relative abundance of Proteobacteria was increased and the abundance of Bacteroides was decreased in ALD samples (p = 0.001) compared with that in HC samples. Fusobacteria levels were higher in AH samples (p = 0.0001) than in HC samples. Untargeted metabolomics was applied to quantitatively screen 103 metabolites from each stool sample. Indole-3-propionic acid levels are significantly lower in AH and AC (vs. HC, p = 0.001). Indole-3-lactic acid (ILA: p = 0.04) levels were increased in AC samples. AC group showed an increase in indole-3-lactic acid (vs. HC, p = 0.040) level. Compared with that in HC samples, the levels of short-chain fatty acids (SCFAs: acetic acid, butyric acid, propionic acid, iso-butyric acid, and iso-valeric acid) and bile acids (lithocholic acids) were significantly decreased in AC. The pathways of linoleic acid metabolism, indole compounds, histidine metabolism, fatty acid degradation, and glutamate metabolism were closely associated with ALD metabolism. Conclusions: This study identified that microbial metabolic dysbiosis is associated with ALD-related metabolic dysfunction. The SCFAs, bile acids, and indole compounds were depleted during ALD progression. Clinical trial: Clinicaltrials.gov, number NCT04339725.

The association between alcohol consumption and cardiometabolic factors and liver fibrosis in metabolic dysfunction‐associated steatotic liver disease and metabolic dysfunction and alcohol‐associated liver disease

Impact of alcohol consumption on metabolic dysfunction‐associated fatty liver disease development and remission: A longitudinal cohort study

Body mass index of 23 or greater is relevant to hepatic steatosis and fibrosis in patients with harmful alcohol use

Mild-moderate alcohol consumption and diabetes are associated with liver fibrosis in patients with biopsy-proven MASLD

Interactions between the metabolic syndrome and alcohol consumption increases the risk of liver disease

Interaction between metabolic syndrome and alcohol consumption, risk factors of liver fibrosis: A population‐based study

Alcohol and Metabolic Syndrome Interaction

Extent to which weight loss contributes to improving metabolic dysfunction-associated and metabolic and alcohol related/associated steatotic liver disease: a study on Japanese participants undergoing health checkups

Impacts of cardiometabolic risk factors and alcohol consumption on all-cause mortality among MASLD and its subgroups

Synergistic and Detrimental Effects of Alcohol Intake on Progression of Liver Steatosis

Characteristics of microbiome-derived metabolomics according to the progression of alcoholic liver disease

Association of metabolic dysfunction‐associated fatty liver disease with gallstone development: A longitudinal study

Metabolic Dysfunction-Associated Steatotic Liver Disease and All-Cause and Cause-Specific Mortality

The Metabolic Syndrome as a Predictor of Nonalcoholic Fatty Liver Disease

Mortality outcomes in individuals with MASLD versus MASLD and increased alcohol intake

Long-term Risks for Cirrhosis and Hepatocellular Carcinoma Across Steatotic Liver Disease Subtypes

Long‐term prognosis of patients with alcohol‐related liver disease or non‐alcoholic fatty liver disease according to metabolic syndrome or alcohol use

Different minimal alcohol consumption in male and female individuals with metabolic dysfunction‐associated fatty liver disease

Prevalence, proportions of elevated liver enzyme levels, and long‐term cardiometabolic mortality of patients with metabolic dysfunction‐associated steatotic liver disease

Increased risk of chronic kidney disease and mortality in a cohort of people diagnosed with metabolic dysfunction associated steatotic liver disease with hepatic fibrosis

Long‐term clinical outcomes in steatotic liver disease and incidence of liver‐related events, cardiovascular events and all‐cause mortality